Following the publication of this article, the authors noted the following errors:
1. The final sentence in the legend of Figure 1 should be 'Data are presented as the mean ± s.e.m. of one-two experiments each in triplicate'.
2. The final sentence in the legend of Figure 3 should be 'Data are presented as the mean ± s.e.m. of two-three independent experiments'.
3. We inadvertently duplicated a flow cytometry histogram in Figure 5C (right hand column 5th row and right hand column 6th row). This has been corrected in the revised version of Figure 5 as presented below: High NHL cell lines to navitoclax and venetoclax in a caspasedependent manner. BCL2
High NHL cell lines were co-treated with navitoclax (1 μM) or venetoclax (1 μM) in combination with flavopiridol at 0, 16.67, 50 or 150 nM (a) or 50 nM (b) for 24 h before assessing effects on MCL-1, BCL-2, caspase-3, PARP and β-actin by western blot. Alternatively BCL2 High cell lines were pre-treated with z-VAD-fmk (50 μM) for 1 h and then co-treated with navitoclax (1 μM) or venetoclax (1 μM) in combination with A-1210477 (5 μM) or flavopiridol (50 nM) for a further 24 h and the effect on apoptosis determined by flow cytometric analysis of Annexin-V/7-AAD staining. Representative flow cytometry histograms in SU-DHL-4 cells from three independent experiments are shown in c and quantified in d. Citation: Blood Cancer Journal (2016) 6, e403; doi:10.1038 /bcj.2016 www.nature.com/bcj
